Metabolomic profiling reveals plasma GlycA and GlycB as a potential biomarkers for treatment efficiency in rheumatoid arthritis

•Biomarkers indicating effectiveness of bDMARD are needed.•Twenty four metabolites differed significantly in RA patients responding to bDMARD treatment before and after therapy.•Eleven metabolites differentiated responders versus non-responders before starting treatment.•In particular, GlycA/GlycB levels were associated with response to bDMARD before and after three months of therapy.